Although a number of studies regarding the PIK3CA gene or PI3K pathway in HER2-positive breast cancer have been reported, they mainly focused on the impact on prognosis or response to anti-HER2 therapy in a metastastic disease [7], [13], [14], [15], [21]. This evidence concerns the gene PIK3CA and breast carcinoma.